All posts by medical

Anatomy

‘Nomadland’ | Anatomy of a Scene – The New York Times

new video loaded: Nomadland | Anatomy of a Scene

transcript

transcript

Hi, Im Chlo Zhao. I am the writer, director, editor, and one of the producers of Nomadland. Hi, may I help you? This scene was shot in the Badlands National Park where Fern is doing a summer camp hosting job. This is a situation where we mix professional and non-professional actors. There are two actors in the scene. There is Fern played by Frances McDormand. Then theres Dave played by David Strathairn This is going to be really exciting. Some of the people that are playing the tourists, theyre actually tourists at the National Park. The one thing I think is interesting to talk about in this scene is everything is scripted and staged. But through casting, cinematography and the editing, our goal is to make you feel as if this is really happening. As if she just showed up and improvised everything. The time of day is very important in shooting a scene like this in the Badlands. The texture of the rocks in the Badlands looks very different, the colors throughout the day. So its that last 25 minutes when the sun already go behind the rocks. It was of the most intense magic hour hustles in the film. Fran has such an interesting body language that I love, that we wanted to bring into Fern. She reminds me of Buster Keaton or Chaplin. You just love seeing how she walks and runs and interacts with the space. And I think that it brings a little bit of humor to it. Frances is the one that came up with those white sneakers that she was wearing. Find anything interesting? Rocks! And then shes got these little pink socks, almost like a child getting lost. Its the first time that shes really embracing being a traveler. And enjoying the exploration. So in this scene shes exploring, but shes also lost at the same time.

Recent episodes in Anatomy of a Scene

Film directors walk viewers through one scene of their movies, showing the magic, motives and the mistakes from behind the camera.

Film directors walk viewers through one scene of their movies, showing the magic, motives and the mistakes from behind the camera.

Read the rest here:
'Nomadland' | Anatomy of a Scene - The New York Times

Anatomy

The On The Forecheck Podcast: Anatomy of an Organizational Failure – On The Forecheck

Click here for a direct link to the episode.

For most fans, this past weekends 4-2 loss to the Detroit Red Wings marked a new low in the recent history of the Nashville Predators. Theyre now 6-9-0 on the season, having lost nine of their past thirteen games.

Its obvious changes need to happen. But therein lies the question: What exactly is the problem?

Thats the topic Nick, Shaun, and Ann tackle in this weeks OTF Podcast episode. How much blame should be on the players? Is John Hynes doing enough to change the direction of the team? And, the juiciest topic on Twitter this weekend, has David Poiles time in Nashville run its course?

You can follow the podcast on twitter at @ForecheckPod.

Nick: @_nsmorgan

Shaun: @SCSOTF

Ann: @AnnK_MamaOnIce

Click the player above to listen; theres a subscribe option built in. You can also find us on Google Podcasts, Apple Podcasts, Stitcher, TuneIn and many more!

If youre having trouble finding the feed, you can add it by URL by using this address: https://feeds.megaphone.fm/on-the-forecheck.

Original post:
The On The Forecheck Podcast: Anatomy of an Organizational Failure - On The Forecheck

Anatomy

Grey’s Anatomy: 5 Most Shameful Things Jackson Did (& 5 He Should Be Proud Of) – Screen Rant

Jackson Avery has had some memorable moments on the show. However, whether they are good or bad is up for the fans to debate.

There are a lot of fan-favorite characters in the compelling medical drama Grey's Anatomy. However, one character that largely goes under the radar is Jackson Avery. Jackson is relatively level headed, intelligent, andhas had a steady evolution from a somewhat callous young resident to a world-class surgeon.

RELATED:Grey's Anatomy: 5 Times Jackson Avery Was An Overrated Character (& 5 He Was Underrated)

Jackson is one of those few for whom it is hard to find any particularly shameful, cringeworthy moments. He has in general a clean slate, although, that doesn't mean he is flawless. After all, no character in Grey's is perfect, which is what makes them flesh and blood. While fans have been proud of some of the gestures he has made, there have also been plenty of times where they have questioned his decisions too.

This was perhaps not no shameful as it was a tad annoying. Jackson did get a bit of a shock when he discovered Catherine had spent the night with Richard the morning of his boards. He was, understandably, a bit distracted thereafter.

However, seeing how rational and cool-headed he was, perhaps he went a littleoverboard when he continued to sulk even at a later date. His mother was a strong and independent woman, who was wise enough to make her own decisions sohe should respected her decision to date Richard. He did become comfortable with the situation later on though and began to root for the couple to be together.

Jackson came from the "celebrated" Avery family, which had been one of the most prestigious and respectable families in the medical community. Before the Harper Avery scandal was revealed, the older surgeon's name was shown to hold value at Seattle Grace (in the same way that Ellis Grey's name was).

Jackson could easily have exploited his family name and got ahead in life for no hospital would have had the guts to turn away Harper Avery'sgrandson. However, he refused to use the name as a crutch to the extent that when he joined Seattle Grace, no one was even aware that he belonged to the Avery family. He wanted his accomplishments to be reflective of his hard work and skills rather than be based on his family name.

Jackson waited until the very last moment to speak up to April about his feelings. April was already at the altar when Jackson decided to confess how he feltin front of a church full of guests and his girlfriend. Later on, it was revealed the two had eloped after fleeing from the church together.

RELATED:Greys Anatomy: 5 Shameful Things April Did (& 5 She Should Be Proud Of)

Jackson's last-minute revelation caused April's fianc Matthew and his girlfriend, Stephanie, extreme humiliationand heartbreak. All this could have been avoided had he told April about his feelings whilethere wasstill time. Matthew and Stephanie were decent people who deserved better than this.

Jackson was assisting Webber in his experiment to develop an artificial pancreas as a cure for diabetes. He felt as though he was wasting his time at first but when the research started showing potential, he actually went ahead and removed his name from it.

This was because Richard's experiment, Jackson thought, might be in the running for the Harper Avery, and if the latter'sname appeared on it, the research would never win the award as that would come across as nepotism. Hence to let Richard have his shot at the prestigious award, Jackson bowed out of the study, which was rather a nice gesture.

Jackson had a spiritual revelation after April almost died. He himself had a near-death experience in the season 15 premiere.

However, instead of informing Maggie (whom he was dating at the time) that he was taking some time off for his spiritual discovery, he simply vanished on her. He only left her a voice mail to tell her he needed to take a step back to look at the bigger picture, but he neither spoke to her nor told her where he was going. This, justifiably, enraged Maggie.All Jackson needed to do was to keep her in the loop which he didn't.

Jackson once saved a little child from a bus that had blown upin the hospital's causeway. The bus had come crashing into the bay and flipped over, with the explosion occurring just as Jackson was trying to save a scared kid, who was stuck inside the overturned vehicle.

RELATED:Grey's Anatomy: 10 Main Characters' Arcs, Ranked Worst To Best

April was deeply upset at the very thought that Jackson might have perished in the burning bus. However, he survived, saving the kid at the same time, a selfless actionhe had every right to be proud of.

Again, this is not shameful per se, especially since Maggie repeatedly came across as skeptical of getting too emotionally involvedin a relationship.

However, was it unfair that Jackson decided to continuously speak to a random woman called Kate, whom he had met during his spiritual outing, and April because he felt that Maggie simply couldn't understand what he was going through? A little.

While Maggie was a bit unfair to Jackson in this argument, one can understand why she was upset as it would hurt anyone to discover that the person they loved had been no qualms talking to other people but refused to open up to her.

In the season 6 finale, fans were shocked to discover a mass shooting take place at the hospital after Gary Clark returned to kill Derek, Lexie, and Webber. Clark eventually found and shot Derek, insisting the other surgeons shouldn't operate or save his life.

At this time, it was Jackson's quick-thinkingthat saved a number of lives, including Derek's, Cristina's, and, of course, his own. Jackson had the brainwave of disconnecting Derek from the monitors so that it appeared that he had flatlined (when he actually hadn't.) This pretense was successful as Gary left the room, not realizing what had happened.

After the devastating plane crash of the season 8 finale, the doctors who had been aboard that fateful aircraft sued the airline for negligence. As many fans know, the tragedy had caused the deaths of Lexie and Mark, both of whom had been close to Jackson Avery.

RELATED:Grey's Anatomy: Most Heartbreaking Deaths, Ranked

While Jackson had initially been on board with their case, he soon changed his mind when he found out that the airline had found a loophole that would cost the hospital greatly. To then question or be sarcastic to Meredith and the others for suing the hospital, even if just for a moment, was genuinely shameful.

After Lexie and Mark's tragic and untimely death, the hospital changed its name from Seattle Grace Mercy West to Grey Sloan Memorial in honor of the two surgeons whose lives had been lost so shockingly.

It was Jackson who came up with this idea for the hospital. As the representative of the Harper Avery Foundation, which had bought the hospital to help it out ofits financial fiasco,hehad the power to suggest such a major change. He made up for his rather insensitiveremark that the doctors needn't have sued the hospital with this very decent gesture.

NEXT:Grey's Anatomy: 5 Times We Were Heartbroken For Jackson (& 5 Times We Hated Him)

Next How I Met Your Mother: Each Main Character's First & Last Line In The Series

Surangama, or Sue, as she is called by many, has been writing on films, television, literature, social issues for over a decade now. A teacher, writer, and editor, she loves nothing better than to curl up on a lazy afternoon with her favorite book, or with a pen and a notebook (a laptop would have to do!) and a foaming cuppa tea on the side.

Original post:
Grey's Anatomy: 5 Most Shameful Things Jackson Did (& 5 He Should Be Proud Of) - Screen Rant

Anatomy

Anatomy of… Katherine Brunt | Sport | The Sunday Times – The Times

FactfileAge 35Height 5ft 4inODIs 116IT20s 88ICC womens ODI bowling ranking 11 (Highest ranking: 1, 2013)ICC womens IT20 bowling ranking 12 (Highest ranking: 1, 2010)

Right armIn her first Test against New Zealand in 2004, when she was 19 years old, her first wicket was Rebecca Rolls, regarded as one of the best batters in the world at the time. Brunt is now Englands leading all-time wicket taker. In recent years she has also developed her batting talent. She credits the former England Women head coach Mark Robinson with this success: Its really been [him] seeing the batsman in me, she told ESPN Cricinfo in 2019. Hes honed me to get the batsman out of me, giving me the

Original post:
Anatomy of... Katherine Brunt | Sport | The Sunday Times - The Times

Anatomy

Janacek’s Jenufa: an anatomy of anguish | Culture | The Sunday Times – The Times

Perhaps the most disappointing cancellation of the lockdown periods was Claus Guths new Royal Opera production of Janaceks Jenufa already well advanced in the rehearsal rooms last March with the mouthwatering cast of Asmik Grigorian, her RO debut, and Karita Mattila in the leading female roles of Jenufa and her stepmother, Kostelnicka Buryova.

Compensation of sorts came last weekend, when Simon Rattle raised his baton at Berlins Staatsoper Daniel Barenboims opera house to conduct Damiano Michielettos new production, socially distanced on stage and closed to the public, with the Finnish soprano Camilla Nylund as the secretly pregnant heroine, and Evelyn Herlitzius as the infanticidal matriarch who kills her stepdaughters baby to protect her own and Jenufas reputation.

The opera, premiered in

Originally posted here:
Janacek's Jenufa: an anatomy of anguish | Culture | The Sunday Times - The Times

Anatomy

Nikiea Redmond and Kirsten DAndrea Hollander Discuss Their 10-Year Documentary with Anatomy of Wings | Slamdance 2021 [Exclusive Interview] – LRM…

Nikiea Redmond and Kirsten DAndrea Hollander directedAnatomy of Wings.

Anatomy of Wings is a ten-year journey for many participants in the documentary.

The film started off as a small film project for young children ended to be a coming-of-age documentary of ten young girls for half their lives under a mentorship program in Baltimore.

Heres the synopsis:

At first, gathered to create an after-school film project, ten Black middle school girls return each week to collaborate with their Black and white mentors on a feature-length documentary about their own coming-of-age in Baltimore City. Weeks turn into years. Then, shortly before the girls high school graduation, a sea of misunderstanding arises about whats to come. The self-defined second family is left to question if their solidarity will survive the realities of living in a world of racial inequity.

It all started out at Dunbar Middle School, where mentors Nikiea Redmond and Kirsten DAndrea Hollander kickstarted an afternoon weekly program called Wings. Initially created for young girls in middle school to learn about video skills, the formal curriculum quickly starts to fade away and the weekly meetings organically begin to shift towards discussing the vulnerabilities of the girls experiences. Through trust, mentorship, and leaps of faith, a deep bond is created with the girls that last the test of time. What was only intended to be a 10-week course ends turning into a 10+ year experience, where the girls are cinematographers with autonomy in framing how their stories are shared with the world.

The ten young women being mentored, included Brittany Backmon, Teshavionna Tazz Mitchell, Shelia Butler, Brienna Brown, Marquise Weems, Danisha Harris, Cami McCrief, Quandra Jones, Tywana Reid, and Quanisha Carmichael. The Wings mentors included Kirsten DAndrea Hollander, Jackie Duvall-Harvery, Jane Cottis, Nikiea Redmond, Kata Frederick, and Cinnamon Triano.

LRMs Gig Patta discussed with co-directors Nikiea Redmond and Kirsten DAndrea Hollander regards to the 10-year documentary of their own lives.

Nikiea Redmond received her bachelors in corporate communications from the University of Baltimore in 2011. Redmond serves as a liaison for political organizations and community groups in East Baltimore. In 2004, she received the Sam Lacy Award for Youth Leadership from The Afro-American Newspaper. The following year, she was the 2015 recipient of the Black Wall Street Journal Award for her work in Baltimore City.

Kirsten DAndrea Hollander is a full-time professor at the Maryland Institute College of Art (MICA, where she directs the MFA Filmmaking program. In 2008, she launched the Wings Video Skills After School Program for Girls, which lead to this documentary. In 2011, she was selected to the Independent Filmmaker Project Fellowship to launch her first feature-length documentary Us, Naked: Trixie & Monkey.

Anatomy of Wings documentary currently streams at the Slamdance Film Festival. Visit http://www.slamdance.com for ticket information.

Watch the exclusive interview below. Let us know what you think.

Source: LRM Online Exclusive, Raw Honey Films

Read more from the original source:
Nikiea Redmond and Kirsten DAndrea Hollander Discuss Their 10-Year Documentary with Anatomy of Wings | Slamdance 2021 [Exclusive Interview] - LRM...

Biochemistry

The future of science education: Q&A with the creator of a new chemistry course – Arizona Daily Wildcat

Laura Van Dorn is a professor at the University of Arizona. She currently teaches chemistry 101A and 101B. CHEM 101A is a general chemistry course and CHEM 101B is an introductory course to organic chemistry and biochemistry. Due to the pandemic, both classes have been switched to a live-online format.

Van Dorn has developed a new, challenging chemistry course: CHEM 130. It is designed to have a year's worth of general chemistry completed in a single semester. CHEM 130 is for students who need the foundations of chemistry and biochemistry, but given their career focus in different areas, will not necessarily go on to take additional chemistry classes. The Daily Wildcat sat down with Van Dorn via email to find out more about the process of starting a new course.

Daily Wildcat: Can you provide a brief description of CHEM 130?

Laura Van Dorn: CHEM 130 will introduce students in nursing and public health majors to the fundamental principles of general and organic chemistry and elements of biochemistry, with a focus on medical, nutritional, and environmental aspects of the discipline.

Current topics in health sciences will be used to guide students in developing a solid background in chemistry that may be applied in their future careers. Critical thinking and pattern recognition will be utilized with the goal of developing skills in problem-solving, applying the foundations of chemistry to new concepts.

Students will be taught to integrate their conceptual and modeling skills with quantitative data to make predictions regarding the behavior of molecules in different environments.

DW: What makes CHEM 130 different from other entry-level chemistry courses?

Van Dorn: CHEM 130 is a one-semester overview of the material, which other chemistry and biochemistry courses typically take several semesters to cover. It is the only course of this kind at UArizona.

It is designed for students who need a fundamental understanding of chemistry and biochemistry, but do not have room in their degree programs for the traditional 2 semesters of General chemistry, two semesters of Organic Chemistry, and two semesters of Biochemistry (which is what Chemistry or Biochemistry majors would normally take).

CHEM 130 will emphasize the elements of chemistry and biochemistry important to public health and nursing fields. It will introduce students to recognizing patterns and making predictions. Demonstrations and activities will be a large part of the course. It can be difficult to visualize some of the concepts in chemistry, thus being able to see the effects of chemicals on different types of matter has the tendency to help students.

DW: Do you recommend those only in the pre-health route to take CHEM 130?

Van Dorn: No, this course is for anyone with an interest in how chemistry applies to every aspect of our lives. Our bodies, our environment, all of it is chemistry.

DW: How would you describe the rigor of this course?

Van Dorn: CHEM 130 will be a challenging class, preparing students for careers in health-related fields. Although no extensive background in math or science will be required before taking the class, students should expect to invest considerable effort in mastering the material. Readings will be assigned before class, and students will complete weekly homework as well as unit assessments.

As the course will be offered in-person and through Arizona Online, students will be able to complete much of the course at their own pace. A three-unit science course does require time outside class, and motivation on the part of the students, but theyll learn some really interesting things.

DW: Is CHEM 130 going to be offered as an alternative for CHEM 151?

Van Dorn: CHEM 130 will be very different from CHEM 151 or its equivalent CHEM 141. CHEM 141 or 151 covers only the first half of General Chemistry. CHEM 130 will encompass all of General Chemistry (i.e. CHEM 141/151 plus CHEM 142/152), in addition to important elements of Organic Chemistry and Biochemistry.

The depths of coverage will, of course, be different, given the course objectives, its target audience, and time constraints, but it is important to stress that CHEM 130 is a much broader class than either CHEM 141 or CHEM 151. CHEM 141 or 151 are suitable for students that need chemistry as a prerequisite for higher-level chemistry classes and have a foundation in math.

DW: Is there anyone else you made and/or designed the class with?

Van Dorn: The course content is my own. I will be working with Celeste Atkins at Arizona Online in order to offer the class online as well as in-person for Fall 2021. Colleen Kelly will be developing the separate lab course, CHEM 130L.

Follow Briana Aguilar on Twitter

Let us come to you. The Daily Wildcat, straight to your inbox. News. Science/Health. Sports. Arts/Lifestyle. You choose. You cancel at any time.

See more here:
The future of science education: Q&A with the creator of a new chemistry course - Arizona Daily Wildcat

Biochemistry

UW chemist and oceanographer named Sloan Fellows – UW News

News releases

February 16, 2021

Two faculty members at the University of Washington have been awarded early-career fellowships from the Alfred P. Sloan Foundation. The new Sloan Fellows, announced Feb. 16, areAshleigh Theberge, an assistant professor in the Department of Chemistry and Jodi Young, an assistant professor in the School of Oceanography.

Open to scholars in eight scientific and technical fields chemistry, computer science, economics, mathematics, molecular biology, neuroscience, ocean sciences and physics the fellowships honor those early-career researchers whose achievements mark them among the next generation of scientific leaders.

The 128 Sloan Fellows for 2021 were selected in coordination with the research community. Candidates are nominated by their peers, and fellows are selected by independent panels of senior scholars based on each candidates research accomplishments, creativity and potential to become a leader in their field. Each fellow will receive $75,000 to apply toward research endeavors.

This years fellows come from 58 institutions across the United States and Canada, spanning fields from evolutionary biology to data science.

Ashleigh Theberge

Theberge is an assistant professor of chemistry. Her research probes the chemical signals that cells use to communicate with one another. The organization of our bodies, with different types of cells taking on discrete functions, depends on this biochemical language.

Were alive because our cells can exchange chemical messages in appropriate ways, said Theberge, who is also an adjunct assistant professor of urology at the UW. All cells human cells, microbes utilize chemical signals to deliver information and influence the properties of other cells.

Jodi Young

Youngis an assistant professor in the School of Oceanography. She studies microbial oceanography, with a focus on the role of marine algae in the carbon cycle. In particular, her research explores polar ecosystems and other extreme environments, and the biochemistry of photosynthesis. Herresearchcombines fieldwork,algal culture manipulationsand biochemical and molecular analyses to uncover the evolution and adaptations of biological carbon fixation in the oceans.

Half of all photosynthesis happens in the oceans, across an amazingly diverse collection of organisms, Young said. My groups research focuses on understanding the underlying physiological and molecular adaptations of marine photosynthesis. Understanding how marine algae have and will adapt to a changing climatereveals insights into how life on Earth evolved and will respond in the future.

For more information, contact Theberge atabt1@uw.edu and Young at youngjn@uw.edu.

Originally posted here:
UW chemist and oceanographer named Sloan Fellows - UW News

Biochemistry

Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing…

NEW YORK, Feb. 18, 2021 /PRNewswire/ --Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced positive top-line data from an investigator-sponsored phase 2 proof-of-concept clinical trial of IMU-838 in primary sclerosing cholangitis (PSC). This single-arm, open-label, exploratory study was designed to investigate IMU-838's potential to improve various biochemical parameters in PSC patients and help determine whether any such activity warrants further investigation in randomized PSC trials. As previously announced, due to the COVID-19 pandemic, only 18 of the targeted 30 patients were enrolled in the study (intent-to-treat population, ITT), of whom only 11 patients completed the full IMU-838 treatment course and were evaluable over the 24-week treatment period (per-protocol population, PP).

The PP population experienced a statistically significant decrease in serum alkaline phosphatase (ALP) levels (p=0.041) after 24 weeks of treatment using 30 mg IMU-838 once daily, as compared to baseline. A consistent individual pattern of a stable decrease in ALP values was observed in the PP population between baseline and week 24, without any single patient showing an increase of more than 20% of ALP. As per the definition of the primary objective of the study, 27.3% of the patients in the PP population had a clinically relevant reduction of serum ALP higher than 25% at week 24, without an increase in liver biochemistry of more than 33%, as compared to baseline. Biochemical endpoints, such as changes in serum ALP, have been used in PSC trials performed by third parties.

Regarding the secondary objectives of the study, no changes in aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total, direct or indirect bilirubin were observed in the ITT or PP populations, as compared to baseline. In addition, despite the limited scope of the data, encouraging results were observed regarding symptoms of inflammatory bowel disease, a common comorbidity for PSC patients, and patient assessments of health-related quality of life. The study also found that IMU-838 is a safe and well-tolerated oral drug for PSC patients and treatment-emergent adverse events were rare and generally mild.

"I am very excited about the effects we have seen in this highly underserved patient population where there is only a small number of cases worldwide and where no pharmaceutical treatment option is currently available," noted Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. "We are also very pleased to see that IMU-838's safety and tolerability profile was confirmed in this patient group. The results from this small, open-label study suggest that IMU-838 merits further clinical testing in PSC. We are in discussions with investigators and leading clinical experts to further evaluate the data set and to explore potential next steps for this indication."

"Currently, no effective treatment options are available for PSC patients and the hepatology community is very keen to see new approaches and clinical programs for the investigation of promising new approaches. I am grateful that Mayo Clinic and Immunic are collaboratively exploring this underserved indication for which liver transplantation is often the only effective option," stated Keith Lindor, M.D., Professor of Medicine Emeritus and former President of the American Association for the Study of Liver Diseases. "Although we are mindful of the small size of this dataset, I do believe the results are noteworthy and merit further exploration. Notable in this small patient cohort is the absolute consistency with which these patients experienced decreases in serum alkaline phosphatase at the 24-week time point."

Study Background and Baseline Characteristics

The single-arm, open label, exploratory study was an investigator-sponsored trial led by Elizabeth Carey, M.D., Professor of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, who had received Investigator Investigational New Drug (IND) approval from the U.S. Food & Drug Administration (FDA) and had been granted Institutional Review Board (IRB) approval to conduct the study. The study was supported by a grant from the National Institutes of Health (NIH) and was conducted at two sites: Mayo Clinic, Phoenix, Arizona (Dr. Carey) and Mayo Clinic, Rochester, Minnesota (John E. Eaton, M.D.), both of which are tertiary referral centers for PSC patients.

The study, for which Immunic provided the study medication, planned to enroll 30 patients with PSC, aged 18 to 75 years, who received 30 mg of IMU-838 once daily for a period of 24 weeks. Enrollment for the study took place between July 2019 and September 2020, but almost all enrollment occurred in 2019 and early 2020. During the COVID-19 pandemic, recruitment for this study was hampered, as patients with PSC are at a high risk of COVID-19 infections and were advised to avoid travel and unnecessary social contacts such as those required to participate in a clinical trial. Together with the investigators, Immunic determined to readout data of the 18 patients who were enrolled prior to the COVID-19 pandemic. The ongoing COVID-19 pandemic also triggered the principal investigator's decision to terminate the study in late 2020, before the intended recruitment goal of 30 patients was reached.

A total of 18 patients started treatment of 30 mg IMU-838 once daily (intent-to-treat population, ITT, n=18). Of these 18 patients, 11 patients received the full 24-week treatment with IMU-838 (per-protocol population, PP, n=11). Due to the high number of discontinued patients during the COVID-19 pandemic and the fact that all discontinued patients in an ITT statistical analysis will be counted as treatment failures at week 24, this analysis focuses mainly on the 11-patient PP population.

Primary Objective

The primary objective of this study was to determine whether IMU-838 reduces serum ALP in adult patients diagnosed with PSC. The main analysis for the primary objective was whether patients could achieve a reduction of ALP at week 24 which is greater or equal to 25%, as compared to baseline, while the AST increase at week 24 is no more than 33%, as compared to baseline. This positive primary outcome was achieved by 3 of 11 patients in the PP population (27.3%, 95% CI: 6-61%). By virtue of inclusion criteria, patients at baseline had to have an elevated ALP value of at least 1.5 times upper limit of normal (ULN).

In addition, time from baseline was calculated as a continuous variable and treated as the primary predictor using a random intercept model which was adjusted for age at baseline and gender. For this longitudinal analysis of ALP from baseline to week 24 in the PP population, the ALP value statistically significantly (p=0.041) decreased by an average of 5.76 IU/L every 30 days (95% CI: -11.29, -0.23; statistical model). The time trend was not statistically significant in the ITT analysis (p=0.578) due to missing data following the high rate of treatment discontinuations during the COVID-19 pandemic.

Secondary Objectives

Secondary objectives were to investigate the liver biochemistry parameters, AST, ALT, and total/direct/indirect bilirubin, as well as the concentrations of proinflammatory cytokines, as compared to baseline. The longitudinal analysis of both AST and ALT as well as total, direct and indirect bilirubin values showed a stable pattern in the PP population with no statistically significant change over time and the confidence interval to include the no-change scenario (AST: average 30 day change 1.22 IU/L, 95% CI: -0.53, 2.97, p=0.170; ALT: average 30 day change 0.85 IU/L, 95% CI -1.46, 3.15, p=0.467, total bilirubin: average 30 day change 0.00 mg/dL, 95% CI -0.01, 0.02, p=0.561, direct bilirubin: average 30 day change 0.00 mg/dL, 95% CI -0.01, 0.01, p=0.861, indirect bilirubin: average 30 day change 0.00 mg/dL, 95% CI -0.01, 0.01, p=0.556). Similar results were found in the ITT population. In addition, a decrease in the Ulcerative Colitis Clinical score was observed in evaluated patients, although the number of assessed patients was limited.

"This was a feasibility study to explore activity of IMU-838 in PSC patients based on biochemical parameters. IMU-838 was found to lead to a statistically significant reduction of serum ALP over time in the PP population, while no trend for increases in ALT, AST or bilirubin was observed," commented Andreas Muehler, M.D., Chief Medical Officer of Immunic. "Despite the challenges we faced due to COVID-19, which severely hindered the enrollment at the two Mayo Clinic sites and which led to an unusually high discontinuation rate and an early termination of the study, we have seen encouraging activity signals for IMU-838 in this patient population. Based on these promising data and, in particular, the improvement in biochemical liver parameters, we will continue to evaluate the potential of IMU-838 as a treatment option for PSC patients. It may also be worthwhile to optimize dose levels of IMU-838 in PSC patients in the future."

For more information on this clinical trial, please visit: http://www.clinicaltrials.gov, NCT03722576.

Conference Call and Webcast Information

As previously announced, Immunic's management team will host a public conference call and webcast today, February 18, 2021 at8:00 a.m. Eastern Timeto discuss the data from the main phase 2 analysis of the CALVID-1 trial of IMU-838 in hospitalized patients with moderate COVID-19, as well as data from the investigator-sponsored phase 2 clinical trial of IMU-838 in primary sclerosing cholangitis.

To participate in the conference call, dial 1-877-870-4263 (USA) or 1-412-317-0790 (International) and ask to be joined into the Immunic, Inc. call. A live, listen-only webcast of the conference call can be accessed at https://www.webcaster4.com/Webcast/Page/2301/39950or on the "Events and Presentations" section of Immunic's website at ir.imux.com/events-and-presentations.

An archived replay of conference call and webcast will be available approximately one hour after the completion for one year on Immunic's website at: ir.imux.com.

About Primary Sclerosing Cholangitis (PSC) PSC is a rare liver disease with a prevalence of approximately 4.15 per 100,000 in the United States, in which the bile ducts in the liver become inflamed, narrow and prevent bile from flowing properly. The exact cause and disease mechanism of PSC are still unknown, but an autoimmune mechanism may play a role. There is an association with inflammatory bowel diseases, most often with ulcerative colitis and less commonly with Crohn's disease. PSC is a progressive disease and, other than liver transplantation, there are currently no approved therapies that have been shown to improve survival in patients with PSC. The estimated time from diagnosis of PSC to death or liver transplant has been shown to be less than 15 years.

About IMU-838IMU-838 is an orally available, next-generation selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase (DHODH). IMU-838 acts on activated T and B cells while leaving other immune cells largely unaffected and allows the immune system to stay functioning, e.g. in fighting infections. In previous trials, IMU-838 did not show an increased rate of infections compared to placebo. In addition, DHODH inhibitors, such as IMU-838, are known to possess a host-based antiviral effect, which is independent with respect to specific virus proteins and their structure. Therefore, DHODH inhibition may be broadly applicable against multiple viruses. IMU-838 was successfully tested in two phase 1 clinical trials in 2017 and is currently being tested in a phase 2 trial in patients with ulcerative colitis. In the third quarter of 2020, the company reported positive results from its phase 2 EMPhASIS trial of IMU-838 in relapsing-remitting multiple sclerosis, achieving both primary and key secondary endpoints with high statistical significance. In the first quarter of 2021, Immunic announced that IMU-838 has shown evidence of clinical activity in its phase 2 CALVID-1 trial in hospitalized patients with moderate COVID-19. Also, in the first quarter of 2021, the company reported positive top-line data from an investigator-sponsored phase 2 proof-of-concept clinical trial of IMU-838 in primary sclerosing cholangitis which was conducted in collaboration with Mayo Clinic. To date, IMU-838 has been tested in more than 800 individuals and has shown an attractive pharmacokinetic, safety and tolerability profile. IMU-838 is not yet licensed or approved in any country.

About Immunic, Inc.Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company witha pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Immunic is developing three small molecule products: its lead development program,IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect; IMU-935 is an inverse agonist of RORt; and IMU-856 targets the restoration of the intestinal barrier function. For further information, please visit: http://www.imux.com.

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's three development programs and the targeted diseases; the potential for IMU-838 to safely and effectively target diseases; the proof-of-concept study of IMU-838 for the treatment of patients with primary sclerosing cholangitis; the timing of current and future clinical trials; the potential for IMU-838 as a treatment for primary sclerosing cholangitis that may be supported by the investigator-sponsored phase 2 proof-of-concept trial data, and any clinical trials, collaborations and approvals relating to such potential treatment; the nature, strategyand focus of the company; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 16, 2020, the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed with the SEC on November 6, 2020, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at http://www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Contact Information

Immunic, Inc. Jessica BreuHead of Investor Relations and Communications+49 89 2080 477 09[emailprotected]

US IR ContactRx Communications GroupPaula Schwartz+1 917 322 2216[emailprotected]

US Media ContactKOGS CommunicationEdna Kaplan+1 781 639 1910[emailprotected]

SOURCE Immunic, Inc.

http://www.immunic-therapeutics.com

Read the original post:
Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing...

Biochemistry

Biochemistry Analysers Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Industry Trends Adopted by the Competitors…

LOS ANGELES, United States:QY Research offers an encyclopedic study of the global Biochemistry Analysers market with holistic insights into vital factors and aspects that impact future market growth. The global Biochemistry Analysers market has been analyzed for the forecast period 2021-2027 and historical period 2015-2020. In order to help players to gain comprehensive understanding of the Global Biochemistry Analysers market and its critical dynamics, the research study provides detailed qualitative and quantitative analysis. Furthermore, readers are offered with complete and thorough research on different regions and segments of the global Biochemistry Analysers market. Almost all industry-specific, microeconomic, and macroeconomic factors influencing the global market growth have been analyzed in the report.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/sample-form/form/2537593/global-biochemistry-analysers-market

The competitive landscape of the global Biochemistry Analysers market is broadly studied in the report with large focus on recent developments, future plans of top players, and key growth strategies adopted by them. The analysts authoring the report have profiled almost every major player of the global Biochemistry Analysers market and thrown light on their crucial business aspects such as production, areas of operation, and product portfolio. All companies analyzed in the report are studied on the basis of vital factors such as market share, market growth, company size, production volume, revenue, and earnings.

Key Players Mentioned in the Global Biochemistry AnalysersMarket Research Report: Thermo Fisher Scientific, Abbott, HORIBA, Siemens Healthcare, Xylem Analytics, Agappe Diagnostics, RMS, MicroLab Instruments, Labindia Instruments

Global Biochemistry Analysers Market by Type: Fully Automated Biochemistry Analyser, Semi Automated Biochemistry Analyser

Global Biochemistry Analysers Market by Application: Hospital and Diagnostic Laboratories, Home Care, Academic and Research Institutes

The report offers great insights into important segments of the global Biochemistry Analysers market while concentrating on their CAGR, market size, market share, and future growth potential. The global Biochemistry Analysers market is mainly segmented according to type of product, application, and region. Each segment in these categories is extensively researched to become familiar with their growth prospects and key trends. Segmental analysis is highly important to identify key growth pockets of a global market. The report provides specific information on the market growth and demand of different products and applications to help players to focus on profitable areas of the global Biochemistry Analysers market.

Key Questions Answered by the Report

Request for customization in Report: https://www.qyresearch.com/customize-request/form/2537593/global-biochemistry-analysers-market

Table of Contents

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

Read the rest here:
Biochemistry Analysers Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Industry Trends Adopted by the Competitors...